GlassScriptPhysician profile
John F Cornett
NPI 1609984418
$12,774.59
in general payments reported to CMS, 2019-2025
57 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $2,005 · 2021: $1,814 · 2022: $1,797 · 2023: $1,993 · 2024: $1,846 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,505 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,504.85 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,868.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,367.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,209.13 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $1,145.67 | 2019-2025 | |
| Abbvie INC. | $1,041.88 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $947.06 | 2019-2025 | Mounjaro, Emgality, Zepbound |
| Glaxosmithkline, LLC. | $598.68 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.02 | 2019-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $306.25 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Janssen Pharmaceuticals, INC | $295.13 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $292.49 | 2019-2021 | |
| Astellas Pharma US INC | $275.82 | 2019-2024 | Veozah |
| Allergan, INC. | $270.65 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.71 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $247.38 | 2022-2025 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cornett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.